A full list of publications can be found at:
Select Publications:
1. Tarawneh R*. The Role of Vascular Constituents in Alzheimer Disease: Is AD Primarily an Endotheliopathy? Invited view and review, Biomolecules, 2023, May 13;13(5):830. *Featured as Editor’s Choice Article
2. Tarawneh R*, Kasper R, Sanford J, Phuah CL, Hassenstab J, and Cruchaga C. CSF VE-Cadherin as a Novel Marker of Endothelial Injury in Preclinical Alzheimer Disease. Annals of Clinical and Translational Neurology, (2022) 9: 1926-1940.
3. Hershey LA, Tarawneh R. Women Need to Be Advised About the Risks of Long-Term Hormone Replacement Therapy. (Editorial) Neurology, 2022 Sep 2;10.
4. Tarawneh R* and Penhos E. The Gut Microbiome and Alzheimer Disease: Complex and Bidirectional Interactions. Neuroscience and Biobehavioral Reviews, 2022 Oct; 141:104814.
5. Hershey L and Tarawneh R. Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations? Neurology, Sep 2021 14;97(11):517-518. Epub 2021 Jul 7. PMID: 34233940.
*Corresponding author
6. Tarawneh R*. Special Issue Paper: Biomarkers: Our Path Towards a Cure for Alzheimer Disease, Biomarker Insights, 2020; (15) 1-15.
7. Tarawneh R, D’Angelo G, Crimmins D, Fagan A, Ladenson JH, Morris JC, Holtzman DM. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease, JAMA Neurol 2016;73(5):561-71.
8. Tarawneh R, Head D, Allison S, Buckles V, Fagan A, Ladenson JH, Morris JC, Holtzman DM. CSF markers of neurodegeneration predict rates of brain atrophy in Alzheimer Disease. JAMA Neurol. 2015;72(6):656-65. (IF 12.3). *This was the first study to show the utility of CSF VILIP-1 levels in predicting rates of brain atrophy in individuals with Alzheimer’s disease
9. Tarawneh R*, Hurth K*, Ghoshal N, Benzinger TLS, Clifford DB, Geschwind M, Morris JC, Galvin JE, Schmidt RE, Cairns NJ. Whipple’s disease masquerades as dementia with Lewy Bodies. Alzheimer Dis Assoc Disord. 2015; 29 (1): 85-89. *contributed equally.
10. Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer Disease. Neurology, 2012, Mar 6; 78(10):709-19.
11. Tarawneh R, Holtzman DM. “The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment”. Cold Spring Harbor Perspectives in Medicine, 2012; 2: 1-16.
12. Tarawneh R, D’Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM. Visinin-like protein-1: A Diagnostic and Prognostic Biomarker in Alzheimer Disease. Annals of Neurology, 2011; 70 (2): 274-85.
13. Tarawneh R, Holtzman DM. Biomarkers in Translational Research of Alzheimer Disease. Neuropharmacology. 2010 Sep-Oct; 59 (4-5):310-22.
14. Tarawneh R, Galvin JE. Potential Future Neuroprotective therapies for Neurodegenerative disorders and Stroke. In Clinics in Geriatric Medicine on Healthy Aging Brain, 2010. 26(1):127-149.

15. Tarawneh R, Holtzman DM. Critical Issues for Successful Immunotherapy in Alzheimer Disease: Development of biomarkers and methods for early detection and intervention. CNS and Neurological Dis. 2009 Apr; 8(2); 144-59.
16. Tarawneh R, Morris JC. New England Journal of Medicine: Journal Watch. Oct 13, 2009. Covering Wolke et al. “Amyloid imaging in mild cognitive impairment subtypes”. Annals of Neurology, 2009 May; 65:557.
17. Tarawneh R, Galvin JE. Distinguishing Lewy body dementia from Alzheimer’s disease. Expert Review of Neurotherapeutics, 2007 Nov; 7(11):1499-516.

Book Chapters:
1. Tarawneh R, Cummings JL. Depression, Psychosis, and Agitation in Stroke. Primer of Cerebrovascular disease, 2nd edition, 2017.
2. Tarawneh R. “The Neuromuscular Junction”. In Novel Challenges in Myasthenia Gravis, Nova Publishers, 2015; 51-66.
3. Tarawneh R, Holtzman DM. “The Clinical Problem of Symptomatic Alzheimer Disease and Mild Cognitive Impairment” In “The Biology of Alzheimer Disease”. Editors: Dennis J Selkoe, David M. Holtzman, and Eckhard Mandelkow. Cold Spring Harbor Perspectives in Medicine, 2012; 9-24.
4. Tarawneh R, Morris JC. “When Mild Cognitive Impairment is really Alzheimer Disease”. In Case Studies in Dementia: Common and Uncommon Presentations. Cambridge University Press, 2011; 18-25.
5. Tarawneh R, Galvin JE. Dementia with Lewy bodies and Other Synucleinopathies. In Clinical Manual of Alzheimer Disease and Other Dementias. American Psychiatric Publishing, Inc, New York, 2011; 193-219.
6. Tarawneh R, Snider B, Coats M, Morris JC. The Clinical Dementia Rating Scale. In Textbook of Principles and Practice of Geriatric Psychiatry. John Wiley & Sons, Ltd, 2010: 170-173.
7. Tarawneh R, Galvin JE. Dementia with Lewy bodies and Other Synucleinopathies. In Textbook of Alzheimer’s and Dementia. Weiner M, Lipton A (Eds) American Psychiatric Publishing, Inc, New York, NY, 2009; 193-218.
8. Tarawneh R, Galvin JE. Neurological signs in old age. In Brocklehurst Textbook of Gerontology and Geriatric Medicine, 2009. Chapter 16, 101-127.

Research in the News:

Awards and Academic Achievements:

  • Patient’s Choice Award, American registry, national level 5/5
  • Compassionate Physician Award, America’s Most Honored Doctors, Top 1%
  • On-time Physician Award, American Registry,
  • Lifetime Achievement Award (Patient’s Choice), American Registry
  • Lifetime Achievement Award (Compassionate Doctor), American Registry
  • Recognition in the Leading Physicians of the World
  • Neurology Residency In-service Training Exam (RITE), 2007, 2008, and 2009; Score 100 % (percentile) – highest score in the nation for level of training in 2007, and across all levels of training in 2008 and 2009